Sorrento Therapeutics, Inc. (SRNE)
After hours:
| Previous close | 1.9900 |
| Open | 1.9700 |
| Bid | 1.9600 x 28000 |
| Ask | 2.0200 x 45100 |
| Day's range | 1.8800 - 2.0600 |
| 52-week range | 1.1500 - 11.0700 |
| Volume | |
| Avg. volume | 10,192,583 |
| Market cap | 781.781M |
| Beta (5Y monthly) | 2.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services (“HHS”) and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento’s Chairman and CEO Henry Ji. G
- GlobeNewswire
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is large and projected to be $8.3 billion in the US by 2025 and has a compound annual growth rate of 16% with a well-defined area of unmet need.Scilex is well-positioned to market and distribute Gloperba: Scilex has
- GlobeNewswire
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4 inhibition.STI-1558 is also a Cathepsin L inhibitor, which may block effective viral entry into host cells without accelerating viral mutations and could work in conjunction with protease inhibition to further protect against COVID-19.STI-1558 showed good oral bioavailability of up to 85% in dogs and
